Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Sasset L, Di Lorenzo A. Sphingolipid Metabolism and Signaling in Endothelial Cell Functions. Adv Exp Med Biol. 2022;1372:87-117.

Villalba JA, Hilburn CF, Garlin MA, Elliott GA, Li Y, Kunitoki K, et al. Vasculopathy and Increased Vascular Congestion in Fatal COVID-19 and Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2022;206(7):857-873.

Simonson PD, Lee AY, Wu D. Potential for Process Improvement of Clinical Flow Cytometry by Incorporating Real-Time Automated Screening of Data to Expedite Addition of Antibody Panels. Am J Clin Pathol. 2022;157(3):443-450.

Dallimore CA, Quelle M, Désir LL, Sham S, Harshan M, Wahl SJ, et al. Calcifying Pseudoneoplasm of the Neuraxis in the Posterior Fossa: A Case Report and Literature Review. Cureus. 2022;14(1):e21562.

Pham K, Gottesdiener L, Simon MS, Trzebucki A, Maldarelli GA, Cisse B, et al. Corrigendum to: Meningovascular Syphilis Presenting as a Brain Mass in an Immunocompetent Male. Open Forum Infect Dis. 2022;9(1):ofab635.

Deshpande AS, Ulahannan N, Pendleton M, Dai X, Ly L, Behr JM, et al. Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing. Nat Biotechnol. 2022;40(10):1488-1499.

Magro CM, Mo JH, Telang G. Localized lymphomatoid papulosis: Unilesional lymphomatoid papulosis, regional lymphomatoid papulosis, and persistent agmination of lymphomatoid papulosis. Clin Dermatol. 2022;40(6):622-638.

Anderson KC, Cantley LC, Dalla-Favera R, Van Dang C, Diaz LA, DuBois RN, et al. The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Prev Res (Phila). 2022;15(11):705-712.

Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, et al. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. Clin Cancer Res. 2022;28(11):2349-2360.

Tsui DC, Aisner D, Nijmeh H, Bao L, Menter A, D Camidge R. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. Clin Lung Cancer. 2022;23(2):e99-e103.